NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.

Workspace · Cancer algorithms · Brain and other nervous system

Brain and other nervous system

Brain and other nervous system · 24,740 new · 18,350 deaths (ACS 2026) · mortality 4.4 per 100k · 5-yr RS 32.9% (SEER)

Mortality 4.4 per 100k (SEER / ACS common-sites). Never an artboard percent.

Lifetime ≈ 0.6% (SEER Stat Facts). 196,343 people living with this cancer in 2023. No encoded screening interval. Not a glioma grade engine.

196,343 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.

Median age at diagnosis 61 · at death 67 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.

Incidence men 7.1 / women 5.1 per 100k · mortality men 5.3 / women 3.6 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.

Most often diagnosed among people aged 65–74. Deaths highest among people aged 65–74. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.

New cases falling 1.4% each year (2014–2023). Death rates falling 0.3% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.

Highest new-case rate: Non-Hispanic White men 8.4 per 100k. Highest death rate: Non-Hispanic White men 6.1 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

Race/ethnicity rates per 100k (SEER Stat Facts)

SEER Stat Facts race and ethnicity incidence and mortality per 100k
Group	Inc. men	Inc. women	Deaths men	Deaths women
Hispanic	5.7	4.6	3.5	2.6
Non-Hispanic American Indian/Alaska Native	5.9	4.6	3.2	2.7
Non-Hispanic Asian/Pacific Islander	4.7	3.4	2.8	2.0
Non-Hispanic Black	4.8	3.5	3.3	2.3
Non-Hispanic White	8.4	6.0	6.1	4.2

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

USPSTF screening pointer

No USPSTF population-screening recommendation is cited for this stub.

ACS / SEER pin only. Not encoded. Not a screening recommendation.

ACS early-detection pointer

ACS 2026 · People without brain-tumor symptoms · ACS (2026): there are no widely recommended tests to screen for brain tumors. Screening here means testing people who have no symptoms. Not an MRI screening engine.

Cited ACS statement only. Not a screening engine. ACS-brain-detect

Surveillance pointer

ACS-brain-follow 2026 · cited only · ACS after-treatment page names close follow-up especially in the first months and years, with exams and imaging such as MRI depending on type and location. Those months are not encoded. Not an MRI screening engine.

Named public source only. Not a personal follow-up calendar. ACS-brain-follow

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names cognitive impairment after brain radiation or chemo, plus hearing or vision change after head or eye radiation. New or worsening memory, thinking, or focus change should be reported right away. Those names are not encoded. Complementary to the living-as pointer. The cited adult brain after-treatment page has no official later-cancer sentence. Not an MRI screening engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a yearly thyroid exam after radiation to the head, neck, or throat, plus a treatment summary and survivorship care plan. Those named tests and plans are not encoded. Complementary to the brain printout. The cited adult brain after-treatment page still has no official later-cancer sentence. Not an MRI screening engine.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

The cited adult brain after-treatment page still has no official later-cancer sentence.

Toxicity pointer

ACS-brain-follow 2026 · empty on purpose · ACS after-treatment page names long-term changes after surgery or radiation. Those late effects are not encoded. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-brain-follow

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later cognitive impairment, hearing loss, and vision change after brain or head radiation or platinum chemo. Those late effects are not encoded. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a yearly thyroid exam after head, neck, or throat radiation. That named test is not encoded. The cited adult brain after-treatment page still has no official later-cancer sentence. Complementary to the brain printout. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

The cited adult brain after-treatment page still has no official later-cancer sentence.

Late toxicity printout

Late toxicity printout — Brain

Acute: ACS names headaches, nausea, fatigue, hair and scalp change, hearing loss, dizziness, seizures, and short-term memory or speech trouble. Late: memory loss, stroke-like symptoms, poor brain function, radiation necrosis, cognitive change, hearing or vision change, lasting fatigue, cavities after head RT or chemo, and low thyroid hormones after head radiation. Monitor: same-day report of headache during RT; later effects from 6 months to years; yearly thyroid exam after head, neck, or throat radiation; lasting fatigue or sleep problems; cavity risk after head RT or chemo. Those names are not encoded. The cited adult after-treatment page still has no official later-cancer sentence. Not an MRI screening engine.

The cited adult brain after-treatment page still has no official later-cancer sentence.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS long-term late names

Cognitive impairment after brain RT or chemo
Hearing loss after brain RT or platinum chemo
Vision change after head or eye RT
Cancer-related fatigue that lasts
Joint or muscle pain after some treatments
Mental health and distress after treatment
Cavities and tooth loss after head RT or chemo
Low thyroid hormones after head or neck radiation

ACS follow-up tests named here

Yearly thyroid exam after head, neck, or throat radiation

Named conditions to monitor

Headache or new neurologic change during RT
Delayed brain effects
Stereotactic single-dose timing
New or worsening memory, hearing, or vision change
New or worsening memory, thinking, or focus
Cancer-related fatigue or sleep problems that last
Joint or muscle pain after chemo, steroids, or hormone therapy
Anxiety, depression, or fear of recurrence after treatment
Cavity risk after head RT or chemo
Fatigue, hair loss, or feeling colder after head or neck radiation
Second-cancer awareness after radiation or chemo
Ask which late-effect tests belong on the follow-up plan

Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS brain-RT names only. Complementary ACS long-term page is named, not encoded. The cited adult brain after-treatment page has no official later-cancer sentence. Not an MRI screening or necrosis-volume engine. No invented trial percent.

Open Brain printout →

NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.

algo-stub-brain · stub · none · v2-stub-brain

SEER 5-year relative survival by stage (cited stub)

Localized 35.3% · Regional 20.1% · Distant 28.0% · All 32.9%

Not a glioma grade engine. Distant RS is the official Stat Facts cell.

Percent of cases by stage (SEER Stat Facts)

Localized 77% · Regional 14% · Distant 2% · Unknown 7%

Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Not a glioma grade engine.

lifetime
Brain and other nervous system birth-to-death
≈ 0.6%

Screening · Surveillance · Toxicity on four golden fixtures

Rio · Plan — survivor

not computed — v2 stub

Cited ACS/SEER population pin only

screening
ACS — no widely recommended brain-tumor screen
Cited ACS 2026 statement only. Not an MRI screening engine.
not encoded
surveillance
ACS follow-up cited — brain months not encoded
Cited ACS after-treatment page only. Not an MRI screening engine.
not encoded
toxicity
ACS late effects cited — brain months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Noah · Plan — skin cancer

not computed — v2 stub

Cited ACS/SEER population pin only

screening
ACS — no widely recommended brain-tumor screen
Cited ACS 2026 statement only. Not an MRI screening engine.
not encoded
surveillance
ACS follow-up cited — brain months not encoded
Cited ACS after-treatment page only. Not an MRI screening engine.
not encoded
toxicity
ACS late effects cited — brain months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Walter · S1 prostate

not computed — v2 stub

Cited ACS/SEER population pin only

screening
ACS — no widely recommended brain-tumor screen
Cited ACS 2026 statement only. Not an MRI screening engine.
not encoded
surveillance
ACS follow-up cited — brain months not encoded
Cited ACS after-treatment page only. Not an MRI screening engine.
not encoded
toxicity
ACS late effects cited — brain months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Priya · average-risk

not computed — v2 stub

Cited ACS/SEER population pin only

screening
ACS — no widely recommended brain-tumor screen
Cited ACS 2026 statement only. Not an MRI screening engine.
not encoded
surveillance
ACS follow-up cited — brain months not encoded
Cited ACS after-treatment page only. Not an MRI screening engine.
not encoded
toxicity
ACS late effects cited — brain months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.

All cancers →Screening →Surveillance →Toxicity →